Drug intelligence / Profile preview

rituximab + polatuzumab vedotin + venetoclax

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

This regimen combines **rituximab** (a monoclonal antibody targeting CD20, leading to B-cell depletion), **polatuzumab vedotin** (an antibody-drug conjugate targeting CD79b, which delivers monomethyl auristatin E (MMAE) to B cells and disrupts microtubules, causing apoptosis), and **venetoclax** (an orally bioavailable small-molecule inhibitor of BCL-2 that triggers apoptosis in BCL-2 dependent malignant cells). The combination is being investigated primarily in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and also in mantle cell lymphoma[1][3][5][7][9]. It is administered intravenously (rituximab, polatuzumab vedotin) and orally (venetoclax). The regimen is not marketed under a unique brand name, being used in clinical trials for high-risk, heavily pre-treated B-cell lymphomas.

Brand names: None known specific to this combination
Other names: rituximab + polatuzumab vedotin + venetoclax

Targets

BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on rituximab + polatuzumab vedotin + venetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab + polatuzumab vedotin + venetoclax.

Explore the full profile